Aetion® Publishes Screening Tool to Identify Candidate Programs for Using Real-World Evidence to Support Effectiveness Claims in FDA Applications in Peer-Reviewed Journal

NEW YORK, Aug. 25, 2023 /PRNewswire/ — Aetion®, the global leader in real-world evidence (RWE) technology and analytics, is pleased to announce that ‘A Screening Tool to Evaluate whether Using Real-world Data to Support an...

U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib) in Combination With Cetuximab to Identify Patients With BRAF V600E Alterations in Metastatic Colorectal Cancer

June 09, 2023 07:02 AM Eastern Daylight Time CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx...